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ABSTRACT  
Background 
Policies encouraging patient choice and hospital competition have been introduced across 
several countries with the aim of improving the efficiency, equity and quality of health care 
services. The English National Health Service (NHS) is an example of a publicly funded health 
system in which hospitals are expected to compete on quality and not price to attract patients, 
who themselves are allowed to choose any hospital that best meets their needs. To date, there 
is limited evidence about the factors that influence patients’ decisions to choose a hospital 
other than their nearest (“patient mobility”) or the implications of these choices on the health 
system.  
 
Methods 
In this thesis, national patient-level datasets and mixed quantitative and qualitative research 
methods were used to investigate the role of choice and competition policies on the delivery 
of specialist cancer services, using prostate cancer as a case study. This included an assessment 
of both the extent and drivers of patient mobility for curative prostate cancer treatment as well 
as the wider system impact of patient mobility and hospital competition on service capacity, 
service configuration, technology adoption and patient outcomes. Semi-structured interviews 
were undertaken with men previously treated for prostate cancer to provide further insight into 
the factors that inform and influence provider choice.  
 
Results  
Patient mobility for cancer treatment far exceeds the 5-10% considered necessary to stimulate 
improvements in quality. One in three men and one in five men bypassed their nearest centres 
for prostate cancer surgery and radiotherapy respectively. Travel time was the dominant factor 
influencing location of care, but its impact was less strong for younger and more affluent 
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socioeconomic groups. Men were attracted to centres offering innovative technologies and 
practices of care as well as centres that employed clinicians with a national reputation for 
prostate cancer. This has resulted in shifts in market share for individual cancer centres 
resulting in a net gain of patients for some centres - “winners” - and a net loss of patients for 
others - “losers”. Surgical centres classified as “losers” had a greater likelihood of closing 
their service. Competition between hospitals has contributed to the rapid adoption of costly 
technology for prostate cancer surgery. However, there is limited evidence to suggest that 
hospital competition improves patient outcomes.    
 
Conclusions 
The thesis demonstrates unequivocally that patient mobility and hospital competition is 
occurring within the NHS. Choice and competition policies rather than a coordinated policy 
towards centralisation have been the most significant drivers in the reconfiguration of prostate 
cancer surgical services in the NHS. Indicators, which accurately reflect the quality of cancer 
treatment delivered, are needed to guide patients’ decision-making. In their absence, patient 
mobility may negatively affect the efficiency and capacity of a regional or national cancer 
service without improvements in patient outcome, and widen socioeconomic inequalities in 
access to care. 
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1. INTRODUCTION 
1.1  Choice and Competition in the NHS in England 
In 2002, the then Labour government embarked on a large scale reform of the health system, 
marking a shift away from targets and transparent public reporting of outcomes, towards the 
introduction of market-related mechanisms to drive improvements in the quality of NHS 
services (Secretary of State for Health 2002). This was accompanied by sustained annual 
increases in NHS funding (Bevan, 2010). Patient empowerment and choice were the core 
components of “Choice and Competition” policy, with a desire to encourage greater patient 
consumerism and mobility between providers (Department of Health, 2005).  
 
In 2003, the government started to encourage a diverse range of providers (public and private) 
to deliver clinical services in order to increase capacity to meet excess demand and drive down 
waiting lists (Department of Health, 2005). A new reimbursement mechanism was also 
introduced - “Payment by Results” (“PbR”) - whereby providers were to be paid according to 
nationally agreed tariffs for hospital services (Department of Health, 2002; Jones & Mays, 
2009). Healthcare Resource Groups (HRGs) supported PbR by providing a classification 
framework of relevant hospital activities representing current practice. With tariffs for services 
essentially fixed, providers were therefore encouraged to compete for “market share” on 
measures of quality rather than price and receive financial rewards accordingly as money 
followed the patients (Le Grand, 2009).  
 
Pilot provider choice schemes were introduced from 2002, including choice for  
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cardiac patients (Le Maistre et al, 2003), choice for patients waiting for elective surgery in 
London  (Burge et al, 2005; Dawson et al, 2004), and choice at the point of referral (Taylor et 
al, 2004). In January 2006, GPs across England were required to offer patients a choice of at 
least four local healthcare providers at the point of referral for elective surgery (Department 
of Health, 2004).   
 
By 2008, patients requiring routine elective treatment (including selected non-surgical 
treatments) had a “free choice” of any licenced NHS (acute or foundation trust) or independent 
sector provider which met the standards set by the CQC and were able to provide care at the 
national tariff rate (Department of Health, 2007b; Dixon et al, 2010b).  
 
The NHS Choices website was introduced in 2007 to support patient choice, and provide 
information on providers and facilitate comparison (Department of Health, 2008). In addition 
to information sourced from the Care Quality Commission (CQC), the website presented 
service user ratings as well as intervention-specific quality ratings in the form of patient 
reported outcome measures and clinical outcome measures (e.g. hip revision rate, emergency 
readmission rate, and mortality rates) (Department of Health, 2008; Greaves et al, 2012; 
Timmins, 2008). The types of performance indicators reported continue to evolve and more 
recently include hospital staff recommendations. The Health and Social care Information 
Centre (www.hscic.gov.uk) and MyNHS (https://www.nhs.uk/Service-
Search/performance/search) websites also provide comparative data on providers.  
 
In 2017, the NHS remains committed to choice and competition policy, encouraging health 
care users to select providers that best meet their health care needs (Department of Health, 
2016). At the same time, the NHS continues to embark on a program of regionalisation and 
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centralisation of specialist health care services including cancer care (Independent Cancer 
Taskforce, 2015).  
 
This mixed policy approach which includes both  “top down” coordination of services and 
competition has evolved in response to the nature of the relationship between the state, the 
medical profession and the public, which had historically shaped the NHS (Jones & Mays, 
2009). The challenge is for these individual policy instruments  to be appropriately balanced 
(Stevens, 2004). However empirical evidence is lacking to understand how such co-existing 
policies may interact or what incentives are necessary to balance them (Baicker  & Levy 
2013). The current evidence suggests that providers and commissioners are preferring to 
choose coordination or cooperation rather than competition as a means of effecting major 
service reconfigurations (Allen et al, 2017).  
 
The next section appraises the literature relating to the impact of choice and competition 
policies in the NHS, and provides the context for this thesis, which intends to focus on the role 
and impact of these policies on the delivery of NHS prostate cancer services.  
 
1.2 Impact of Choice and Competition policy in the NHS 
1.2.1 Awareness and Implementation 
The 2009 Kings Fund Patient Choice survey of 2,181 patients, who had been referred for a 
hospital outpatient appointment in the previous 2 weeks, provides the main evidence with 
respect to the awareness and implementation of choice policies (Dixon et al, 2010a). It 
highlighted two main issues. First, the lack of awareness amongst patients that they had a 
choice of provider for routine elective treatment (only 45% of those surveyed were aware prior 
to visiting their GP that they had a choice). Second, there appeared to be variation in the 
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implementation of choice of provider at the point of referral (only half of all patients recall 
being offered a choice) (Dixon et al, 2010a), which has likely resulted from a failure to engage 
with GPs in the choice process. GPs had initially experienced technical difficulties with the 
“choose and book” electronic system, which had been implemented to facilitate specialist 
hospital referrals. In addition, many GPs did not “buy-in” to the patient choice agenda and its 
expected benefits (Dixon et al, 2010a; Rosen et al, 2007; Sanderson et al, 2013). Others 
reported difficulty in advising on providers outside their local area, instead relying on the their 
own knowledge of local providers (Sanderson et al, 2013).  
 
1.2.2 Information sources 
It was expected that individuals would use comparative performance data in order to make 
informed choices about their health care provider. However current evidence suggests that 
patients rarely search for health quality information, don’t trust it, or don’t use it in a rational 
way to make choices (Fung et al, 2008; Marshall & McLoughlin, 2010). The Kings Fund 
survey found that that only 4% of patients used the NHS Choices website when making 
decisions about treatment provider, with the majority of patients reliant on advice from their 
friends and family network, prior experience, and  GP (Dixon et al, 2010a).  
 
1.2.3 Patient choice 
In order for choice policies to stimulate improvements in provider quality, it is expected that 
some patients will select a provider based on quality and be prepared to move beyond their 
expected provider (usually the nearest) to other providers for a particular service. In theory it 
is anticipated that even movement of between 5-10% of users will provide the necessary 
incentives to improve quality (Le Grand, 2009). However, a major critique is that there is still 
  
14 
 
limited evidence that such policies have affected where patients’ ultimately receive treatment.  
(Pollock et al, 2012).  
 
The London Patient Choice Pilot (LPCP) evaluation based on 19,976 actual visits for selected 
ophthalmic, orthopaedic, ENT (Ear Nose and Throat), urology and general surgery procedures 
demonstrated that 65.5% of patients travelled beyond their local providers in order to receive 
quicker treatment (Dawson et al, 2004). However this was in a controlled environment where 
transport was free for patients choosing alternative providers and patients had already been 
waiting longer than 6 months for procedures at their local hospital (Burge et al, 2005). In the 
Kings Fund patient choice study, 31% of individuals surveyed went to a non-local provider 
for the last secondary care episode (Dixon et al, 2010a).  
 
Using Hospital Episode Statistics data, Kelly and Tetlow demonstrated that the percentage of 
patients receiving elective surgery at their nearest Trust fell year on year from 2003/2004 to 
2010/11. In 2003/2004, 68% of hip replacements and 77% of hernia operations were 
performed at the patient’s nearest Trust (Kelly & Tetlow, 2012). By 2010/11, this had fallen 
to 54% and 61% respectively. However, a notable caveat is that the study did not take into 
account whether the nearest Trust performed the specific intervention in question.  
 
Whilst there is some evidence that patients in the NHS are prepared to move to alternative 
centres for secondary care treatment, it is inconsistent and does not include cancer care.  
 
1.2.4 Equity  
There is a concern that patient choice may exacerbate socioeconomic inequalities in access to 
services and the quality of care received (Dixon & Le Grand, 2006; Fotaki, 2010). However, 
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the results to date from studies using data on actual patient visits in the NHS have been 
equivocal. The London Patient Choice Pilot, demonstrated that patient’s age was positively 
associated with staying at the local hospital to which they were originally referred and that 
men are more likely than women to move to alternative hospitals (Dawson et al, 2004). This 
is in keeping with another study that found that elderly and more income-deprived patients are 
more likely to choose their nearest hospital for elective hip surgery (Beckert et al, 2012). 
However, a study focusing on socioeconomic differences in the choice of centre for coronary 
artery bypass grafting found that income was a poor predictor of responsiveness to choice 
policies, and that sicker patients were more responsive to differences in quality (Gaynor et al, 
2016).  
 
1.2.5 Efficiency  
At the time of introducing choice and competition policies, the government attempted to 
encourage a diverse range of providers (public and private) to deliver clinical services in order 
to increase the capacity of the system to ensure sufficient choice was available to meet excess 
demand (Department of Health, 2005). However, there was a concern that creating spare 
capacity would result in inefficiencies if the increased costs of doing so were not off-set by 
quality and efficiency gains elsewhere (e.g. increased productivity) (Jones & Mays, 2009). 
However, to date there has been no evidence to suggest that such system-level inefficiencies 
have occurred (Farrar et al, 2009; Fotaki, 2014).  
 
In addition, studies have demonstrated a reduction in elective waiting lists and average length 
of stay following the introduction of Choice and Competition policy (Cooper et al, 2011; 
Cooper et al, 2009; Dawson et al, 2007; Gaynor et al, 2013; Moscelli et al, 2017; Siciliani & 
Martin, 2007). However, it is thought that these improvements have instead resulted from 
  
16 
 
increased NHS investment on staffing capacity, as well as other target-driven performance 
management policies introduced during this time rather than market based reforms (Bojke et 
al, 2014; Brereton & Vasoodaven, 2010; Fotaki, 2014).    
 
1.2.6 Quality  
The impact of hospital competition on the quality of services in the English NHS remains 
unclear (Fotaki, 2014; Oliver, 2012). Three large econometric analyses reviewing the impact 
of post 2006 NHS choice policy reforms on quality, reported that hospitals located in the most 
competitive market areas, i.e. where patients have high levels of provider choice, had superior 
clinical quality (in terms of mortality from acute myocardial infarction (AMI)) compared to 
hospitals facing less competition (Bloom et al, 2015; Cooper et al, 2011; Gaynor et al, 2013).  
 
In the study by Cooper et al, the lower 30-day acute myocardial infarction mortality rates were 
attributed to wider improvements in hospital performance which had been stimulated by the 
need to compete for elective surgical patients (e.g. cataract surgery) (Cooper et al. 2011). A 
later study by Bloom et al, attempted to demonstrate that the observed improvements in 
clinical quality in hospitals located in the most competitive market areas are due to better 
management practices, which has likely influenced care across medical and surgical 
specialities (Bloom et al, 2015).  
 
However, these econometric studies have received a lengthy critique. First, they fail to 
acknowledge that mortality rates across all hospitals were falling during this time-period and 
that differences in mortality could be attributed to the slowing down of mortality declines in 
less competitive markets rather than improving performance in more competitive areas (Mays, 
2011). Second, there is no explanation as to how competition in the elective surgery market 
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would affect outcomes for acute myocardial infarction (Pollock et al, 2012). Third, the studies 
do not attempt to explicitly link the effect of patient choice and competition between providers 
for a particular elective procedure (e.g. hip or knee replacement) on individual patient 
outcomes. (Bevan & Skellern, 2011). Lastly, the study findings are at odds with two previous 
studies analysing the impact of the 1990s internal market which demonstrated reductions in 
clinical quality in the most competitive markets (Propper et al, 2008; Propper et al, 2004).  
 
A more recent NHS study focusing on the relationship between hospital market competition 
for elective hip replacement surgery and improvements in outcome (measured using the 
Oxford Hip Score - a patient reported outcome measure) found that hospital competition had 
no significant influence on patient outcomes (Feng et al, 2015). Conversely, another NHS 
study found that hospital competition was correlated with a reduction in 30-day mortality after 
a cardiac valve replacement (Diller et al, 2014).  
 
When considered together these studies demonstrate that there is considerable uncertainty 
regarding the role of hospital competition in stimulating improvements in health care quality. 
In addition, there has been little or no published data investigating what the impact of patient 
mobility has been on individual providers; for example, the effect on capacity and practices 
of care if patients are indeed choosing a hospital other than their nearest. The NHS is 
effectively a closed box system and assuming the number of patients requiring treatment for 
any one condition remains stable or increases, the mobility of patients is likely to have an 
effect on the efficient utilisation of available capacity of individual providers and their 
subsequent funding (given that this follows the patient). Equally, centres may have to respond 
in some way to prevent local patients from leaving, or to attract new patients for a particular 
intervention, but the current NHS literature does not provide any evidence as to how this may 
occur.   
  
18 
 
 
1.3 Choice and Competition policy and NHS cancer care services. 
Within cancer care,  inequalities in service provision, access and survival have persisted across 
England and Wales over the last two decades (Berglund et al, 2012; Bungay, 2005; 
Department of Health, 2013; Haward, 2006; Hoskin et al, 2013; Jack et al, 2003; Palser et al, 
2009; Rachet et al, 2010; Royal College of Surgeons of England, 2014; Williams & 
Drinkwater, 2009). By allowing patients to select a provider that best meets their needs and 
by encouraging providers to compete in order to stimulate improvements in quality, it could 
be argued that choice policies have the potential to minimise these inequalities.  
However, to date there has been no research investigating their impact within cancer services. 
There are also several reasons to question whether choice policies are relevant to cancer 
patients and whether such policies are able to drive meaningful improvements in quality. Some 
of the potential issues are outlined below, many of which are also likely to be relevant to other 
specialist disease areas.  
 
1.3.1 Centralisation versus a competitive environment 
There is robust evidence that higher case volume and greater experience in managing cancers 
both at the provider and individual physician level is associated with improved survival 
outcomes (Birkmeyer et al, 2002; Halm et al, 2002; Wouters et al, 2009). For prostate cancer, 
the incidence of post-operative complications, positive surgical margins and late urinary 
complications are reduced when performed by “high volume” surgeons in “high volume” 
centres (Van Poppel & Joniau, 2008; Vickers et al, 2009). As a result, NHS Trusts have been 
undergoing reconfiguration of their cancer services since the early 2000s with greater 
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centralisation of surgical services (National Institute for Health and Care Excellence, 2002; 
NHS England, 2014).  
 
However, such organisational changes limit the potential for patient choice and competition 
between providers and plans for further reconfiguration of cancer services are continuing. In 
2015, the NHS independent cancer task force recommended the creation of “Cancer 
Alliances” across England to implement its vision for improving the quality of cancer care 
services across the cancer care continuum (from prevention to survivorship) (Independent 
Cancer Taskforce, 2015). Alliances are expected to coordinate the efforts of a wide 
stakeholder set (including Clinical Commissioning Groups (CCGs), patients, and providers) 
to strengthen regional commissioning of cancer services and achieve effective implementation 
of its strategic goals at the local level through the 44 newly developed national  Sustainability 
and Transformation plans (“footprints”) (NHS England, 2016 ). At its core is the expectation 
that services should meet the needs of the local population, and tie in with existing health 
service infrastructure and referral patterns within pre-determined geographical boundaries. It 
remains unknown how such changes could act to mitigate the effect of patient choice and 
hospital competition.  
 
1.3.2 Time-frame for choice  
Many common cancers are time sensitive, requiring the prompt initiation of treatment. This 
therefore limits the potential for making informed decisions about treatment providers through 
a review of available performance indicators. In addition, patients may have to choose between 
different treatment options even prior to considering where they receive their care, which for 
many may be too much of an additional burden given the difficulties encountered in selecting 
between cancer treatments (Clark et al, 2003; Clark et al, 2001; Davison & Goldenberg, 2003).  
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Some patients may consider moving to alternative providers to receive quicker treatment. 
However for cancer care, extensive efforts have been made to ensure prompt diagnosis and 
treatment of suspected cancers through a system of defined targets, (Department of Health, 
2000; Department of Health, 2007a; NHS England, 2015) thus reducing this as a driver to 
move.  
 
There are also significant time and financial constraints that a decision to move can have on 
an individual seeking treatment. Treatment options are complex and may last for many months 
when considering chemotherapy or radiotherapy, thus limiting the opportunity to receive 
treatment out of area if so desired. For example, radiotherapy for prostate cancer or lung cancer 
can entail between 6-8 weeks of daily treatment.  
1.3.3 Comparative health information in cancer care 
It is expected that patients are able to select the provider that best meets their needs through a 
comparative review of available options. The NHS Choices website was therefore developed 
to provide this information. However, in cancer care there is lack of clarity as to the optimum 
indicators for measuring performance at the provider and individual physician level given the 
multidisciplinary nature of cancer treatment (Burns et al, 2016).  
 
Outcomes from individual surgeons are now starting to be published for bowel and oesophago-
gastric cancer (with other cancers to follow) (Royal College of Surgeons of England, 2016a; 
Royal College of Surgeons of England, 2016b). However, there is no consensus as to how best 
to measure performance of other surgical procedures such as a radical prostatectomy or cancer 
treatments such as radiotherapy.  
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In the absence of clear comparative health information on cancer care providers, it is unclear 
from the literature what information patients use to make decisions regarding their location of 
cancer treatment. A concern is that patients will be reliant on informal sources of information 
(e.g. word of mouth) when making decisions regarding their provider (Victoor et al, 2012), 
which may result in choices that do not ultimately improve their health outcomes.  
 
1.4  Rationale for investigating impact of choice policies in prostate 
cancer  
Given the heterogeneous nature of cancers in terms of their clinical presentation, method of 
diagnosis, treatment options and prognosis it is necessary to study the impact of provider 
choice policies within a single cancer site. For the purpose of this research, I have selected 
prostate cancer.  
Prostate cancer is the most common malignancy in men, with approximately 40,000 new cases 
diagnosed annually in the United Kingdom (34,000 with non-metastatic disease) (Royal 
College of Surgeons of England, 2016c). Compared to other common cancers such as breast, 
bowel and lung, the biology of the disease is such that in the non-metastatic setting, outcomes 
are not necessarily influenced by treatment delay. Due consideration can be made for the 
preferred strategy, more so than other malignancies where: (1) the optimal evidence based 
management strategy is often already clearly defined; (2) patients may present acutely with 
complications associated with localised/locally advanced disease requiring emergency 
intervention. 
 
There is also evidence of regional variation in availability of prostate cancer services across 
England. Currently, men with non-metastatic prostate cancer are managed within specialist 
multidisciplinary teams (composed of one or more hospital) which usually provide all 
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essential treatments. The National Prostate Cancer Audit (NPCA) has highlighted national 
variation in the treatments offered by specialist multidisciplinary teams (SMDTs) and 
therefore provider choice may facilitate access to cancer treatments that are not available 
locally (Aggarwal et al, 2016).  
 
Even for providers offering the same modality of treatment e.g. radical prostatectomy (RP) or 
external beam radiotherapy (EBRT) there is variation in the technology or technique used. For 
instance, radical prostatectomy may be performed as an open, laparoscopic or robot-assisted 
procedure (Ficarra et al, 2009). Likewise, external beam radiotherapy for prostate cancer, may 
be delivered with 3D conformal techniques, intensity modulated radiotherapy (IMRT), 
stereotactic beam radiotherapy (SBRT) or using proton beam therapy (only available outside 
of the UK currently) (Sheets et al, 2012; Tree et al, 2014). Patients may therefore choose to 
move to another hospital either because the perceived quality of that hospital is thought to be 
better or because they prefer to be treated using a particular technique that is not available 
locally.   
 
Finally, as with other cancer and non-cancer specialist sites, policies in the NHS continue to 
promote the reconfiguration of prostate cancer surgical services with a view to creating higher-
volume surgical units  (NHS England, 2014). Both choice and competition as well as 
centralisation attempt to achieve gains in patient outcome, however they require different 
health system configurations and provider incentives. Finding the right balance between the 
two is therefore key (given that centralisation may negatively affect choice and competition) 
but there is currently limited evidence to guide how best to achieve this.  
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2. RESEARCH DESIGN OVERVIEW   
2.1 Aims and Objectives 
The PhD aims to evaluate the impact of NHS choice and competition on prostate cancer 
services using a mixed methods research design. There are five main research objectives. 
 
1. To evaluate the empirical evidence for patient mobility in elective secondary care 
services in countries that have introduced patient choice policies. 
 
2. To determine to what extent men diagnosed with prostate cancer in the NHS travel 
beyond their nearest treatment provider for curative treatment, and the patient and 
hospital characteristics associated with this mobility.  
 
3. To assess the impact of patient mobility on individual providers with respect to their 
net gains and losses of patients.  
 
4. To investigate the impact of hospital competition on patient outcomes for men 
receiving treatment for prostate cancer.  
 
5. To understand what factors inform and influence where patients choose to receive 
prostate cancer treatment. 
 
The outputs of this research are expected to provide a greater understanding of how NHS 
cancer patients are responding to provider choice policies and what implications this may have 
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on the future organisation and delivery of cancer services and mechanisms for supporting 
patient choice and quality improvement.   
2.2  Empirical approach to investigating patient choice 
Previous studies have attempted to identify the extent to which patients actively choose their 
health care provider and the factors that influence this (Victoor et al, 2012). However, these 
are largely based on data derived from interviews, and surveys, which ask individuals about 
recent health care episodes or hypothetical scenarios (Albada & Triemstra, 2009; Combier et 
al, 2004; Dixon et al, 2010a; Finlayson et al, 1999; Schwartz et al, 2005). 
Patient registration data from actual hospital episodes (revealed preferences) have been used 
in other studies to assess whether patients are choosing (Gutacker et al, 2016; Haynes et al, 
2003). However, in reality this is limited as it is not possible to ascertain whether the patterns 
of service utilisation represent an active choice by the patient alone or are a consequence of 
pre-defined referral pathways, physician preferences or issues with capacity at their local 
provider. Clinicians in particular play a key role in informing and facilitating the choice 
process and the decision to receive treatment at a particular provider.  
 
Given the inherent difficulties associated with establishing active choice using data on 
revealed preferences, one can instead ask a different empirical question: namely, whether there 
is evidence that patients receive care at hospitals other than their nearest. This question is 
related to the concept of “patient mobility”.  
 
Patients travelling beyond their nearest provider are considered to have moved which is used 
as a proxy for “choice”.  This is based on the assumption that patients’ act to minimize their 
travel times and would therefore be expected to receive treatment from their nearest provider 
(Burge et al, 2004; Victoor et al, 2012).  
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From a quantitative perspective, patient mobility is derived from knowing where a patient 
lives and where they move to for a health care intervention or service given the available 
choice of providers. This defined the empirical approach for the quantitative analyses.  
 
In addition to the quantitative analyses, in-depth qualitative interviews were planned with men 
previously treated for prostate cancer in order to gain a more nuanced and in-depth 
understanding of the nature of the choices patient are expected to make. In particular, to what 
extent and in what way patients want to be given these choices as well as the factors informing 
and influencing their decisions regarding treatment location.  
 
2.3 Study Design  
This section provides an overview of the research design and data sources I used in the thesis. 
Each study component described below was designed to address a specific research objective. 
The results of these analyses have been presented in the form of six empirical research papers. 
Four have been published in the peer reviewed literature and two are currently under review.   
 
The first component of the research was a systematic review of the published international 
literature to assess whether there is any empirical evidence of patient mobility for elective 
secondary care services in response to provider choice policies. The systematic review was 
also intended to inform the quantitative component of the study, both in terms of the optimum 
methodology to use to assess the determinants of patient choice and to guide which hospital 
characteristics to consider within the multivariate regression analyses. The output of this 
component of the research produced a published research paper which is presented in the 
results section:  
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“Patient mobility for elective secondary healthcare services in response to patient choice 
policies: a systematic review”  
 See Chapter 3, Pages 32-58  
 
The second component of my research study was a quantitative analysis of patient mobility 
and its determinants using data on actual patient visits for curative prostate cancer treatment 
in the English NHS. Patients receiving radical prostate cancer surgery and radical radiotherapy 
were considered as two separate populations given the variation in the duration and intensity 
of these two treatments and the availability of these services in the English NHS. Patients 
diagnosed with metastatic disease were excluded as treatment options are standardised, and 
the need for rapid institution of treatment precludes the ability to choose a treatment provider 
in most instances.  
 
The systematic review was integral in defining the optimum methods to use within this 
component of the study. For the first part of the analysis I used a hospital bypassing model 
(Varkevisser & Van Der Geest, 2007) to estimate the proportion of men with prostate cancer 
who travelled beyond their nearest provider for a particular treatment. The second part of the 
analysis involved using conditional logit regression, a statistical method widely used in the 
econometric choice literature, to analyse the determinants of patient choices by modelling the 
odds that a patient moved to a particular hospital as a function of travel time and hospital and 
patient characteristics (Beukers et al, 2014; McFadden, 1973). The outputs of the research 
produced two published empirical research papers relating to prostate cancer surgery and 
prostate cancer radiotherapy, which are presented in the results section:  
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“Determinants of patient mobility for prostate cancer surgery: a population-based study 
of choice and competition” 
See Chapter 4, Pages 59-73 
“Hospital quality factors influencing the mobility of patients for radical prostate cancer 
radiation therapy: a national population based study” 
See Chapter 5, Pages 74-86 
 
The third component of the research study was designed to address the impact of patterns of 
patient mobility on individual providers, specifically their net gains and losses of patients. 
This component of the study was undertaken in light of the results from the previous analyses 
(Chapters 4 and 5), which had demonstrated that large numbers of patients travelled beyond 
their nearest provider for surgery and radiotherapy in the English NHS. These gains and losses 
were analysed in the context of the intensity of spatial competition faced by individual 
treatment centres. This analysis was integral to our understanding of the impact of these 
policies on NHS providers given that money follows the patient and therefore decreases in 
patient numbers could affect the viability of the centre.  
 
The analysis focusing on the impact of patient mobility on individual radical radiotherapy 
treatment providers, was included as part of the earlier analyses reviewing patient mobility 
patterns for prostate cancer radiotherapy in Chapter 5 “Hospital quality factors influencing 
the mobility of patients for radical prostate cancer radiation therapy: a national 
population based study”. 
 
With respect to prostate cancer surgery, it was noted during the time-period of the analysis 
(2010-2014), detailed in Chapter 4 “Determinants of patient mobility for prostate cancer 
surgery: a population-based study of choice and competition”, that some centres closed 
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their radical prostatectomy service. At the same time, there was an increase in the numbers of 
centres performing robot-assisted procedures. The subsequent analysis in Chapter 6 therefore 
investigated whether there was an association between the net gains and losses of patients by 
individual providers and the intensity of hospital competition, on both the observed closures 
of centres and the adoption of robotic surgical equipment. The output of this component of the 
research was published as a separate empirical research paper:  
 
“Effect of patient choice and hospital competition on service configuration and 
technology adoption within cancer surgery: a national population based study” 
See Chapter 6, Pages 87-98 
 
The fourth component of the study analysed the impact of hospital competition on patient 
outcomes following prostate cancer surgery using multilevel regression modelling. The 
creation of a competitive environment to support patient choice and to provide incentives for 
hospitals to compete with each other is in conflict with policies that seek to centralise services 
into fewer centres. Centralisation aims to improve quality by eradicating very low volume 
surgery and to increase the number of procedures performed by remaining centres. To assess 
the effects of these two policies, the analysis in this chapter compares the relative impact of 
both hospital procedure volume and hospital competition on patient outcomes following a 
radical prostatectomy whilst adjusting for relevant case-mix criteria. The results of the 
analysis have been presented as a research paper, which has been submitted for publication:  
 
Impact of hospital volume and hospital competition on patient outcomes following 
prostate cancer surgery: a national population-based study 
See Chapter 7, Pages 99-128 
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The fifth component of the study utilised qualitative research methods to understand what 
factors inform and influence where patients choose to receive prostate cancer treatment. This 
involved interviews with men previously treated for prostate cancer. Men were recruited 
through a UK wide prostate cancer support organisation called “Tackle prostate cancer” which 
is composed of 55 member groups.  Semi-structured interviews were undertaken with twenty-
five men and the results of the analysis have been presented as a research paper, which has 
been submitted for publication:  
 
“Hospital choice in the context of a cancer diagnosis:  a qualitative study” 
See chapter 8, Pages 129-161 
 
The quantitative and qualitative components of the research were intended to be 
complimentary as part of a mixed methods approach to understanding how patient choice was 
operating within the NHS. Both sets of analyses were undertaken during the same time-period 
and continually evolved as part of an iterative process. For instance, factors identified within 
the qualitative component that have influenced choice of prostate cancer provider were 
assessed within the empirical model using data on actual patient visits. Likewise, the findings 
of the quantitative component influenced the sampling framework and the topic guide for the 
semi-structured interviews.  
 
During the course of the study it was also decided to interview prostate cancer specialists 
(Urologists, Oncologists) working in England to help triangulate and contextualise the 
findings from the qualitative and quantitative studies. In total, I spoke to twenty specialists 
across England. The findings provided further depth to the interpretation and policy 
implications of my empirical findings, but have not been reported as a specific chapter in the 
thesis. 
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2.4  Data Sources 
Data for the quantitative component of the study was made available through the National 
Cancer Registration Service in England (NCRS), which provided a linked patient level extract 
incorporating three data sources – Cancer Registry, Hospital Episode Statistics (HES), and 
The National Radiotherapy Dataset (RTDS). At the start of the PhD, linked data was available 
for men treated between 2010-2014 inclusive. 
 
I had access to the data through my affiliation with the National Prostate Cancer Audit (NPCA) 
based at the Clinical Effectiveness Unit of the Royal College of Surgeons. The PhD research 
project was designed and developed by me prior to receiving funding from the National 
Institute for Health Research. The PhD project fits within the wider service evaluation projects 
that the NPCA undertakes to provide a better understanding of the determinants of variations 
in processes and outcomes of prostate cancer care.  
 
Other data sources available through the NPCA include:  
 
1. NPCA Organisational survey – a comprehensive review of the configuration of 
prostate cancer services in England also detailing the availability of essential 
diagnostics, staging and therapeutic facilities (e.g. robotic surgery)(Royal College of 
Surgeons of England, 2014). 
 
2. Performance indicators – these were developed as part of the NPCA using Hospital 
Episode Statistics and include length of stay, 30-day emergency re-admission rates 
and incidence of urinary complications within 2 years of surgery. Data was available 
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for men who underwent a radical prostatectomy between 2008-2011 (Royal College 
of Surgeons of England, 2016c).  
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2.5 Ethics  
2.5.1 Quantitative Component 
Anonymised non-identifiable secondary level patient data from the National Cancer 
Registration Service (NCRS) was used to undertake the quantitative analysis. The personal 
details only included age, ethnicity and lower layer super output areas (LSOAs) and no further 
identifiers. Regulatory approval, data security and governance procedures had already been 
established as part of the NPCA through which the data was available. Given that the PhD 
involved the use of anonymised secondary data, NHS REC approval was not sought in 
accordance with their guidelines. I received approval from the NPCA data controller, The 
Health Quality Improvement Partnership (HQIP), to use data collected from the audit for the 
purposes of my research. 
 
2.5.2 Qualitative component  
This study involved in-depth interviews with human subjects regarding personal and 
potentially sensitive issues related to their health, health care or in the case of health care 
professionals their place of work. It was therefore essential that the research methodology 
employed ensured the privacy, confidentiality and respect of all participants. 
 
Participants were not recruited from the NHS and no component of the research took place on 
NHS premises, therefore NHS ethics was not required. Approval from the LSHTM 
Observational/Interventions Research Ethics Committee was therefore sought on 29th April 
2015. Approval was granted on the 11th June 2015.  See Appendix A (page 204) for a copy 
of the ethics approval.  
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3. RESULTS CHAPTER 1  
3.1 Systematic Review  
The first component of the research was a systematic review of the published literature to 
assess whether there is any empirical evidence of patient mobility for elective secondary care 
services in response to patient choice policies. The results have been presented in the form of 
the published article.   
 
3.2 Research paper 1 
Patient mobility for elective secondary healthcare services in response to patient choice 
policies: a systematic review 
 
The online PDF can be accessed at: 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5502904/pdf/10.1177_10775587166546
31.pdf  
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4. RESULTS CHAPTER 2 
4.1 Patient mobility for radical prostatectomy 
The second component of my thesis was a quantitative analysis of patient mobility and its 
determinants using data on actual patient visits for curative prostate cancer treatment in the 
English NHS. This chapter focuses on patient mobility for radical prostate cancer surgery and 
the results have presented in the form of the published paper. The supplementary material 
referred to in the paper is available at the end of this section.    
 
4.2 Research paper 2 
“Determinants of patient mobility for prostate cancer surgery: a population-based study 
of choice and competition” 
 
This paper has been embargoed pending open access publication. Hard copy of complete 
thesis available in LSHTM library.  
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5. RESULTS CHAPTER 3 
5.1 Patient mobility for radical radiotherapy 
After analysing the determinants of patient mobility for radical prostate cancer surgery, this 
chapter focused on patient mobility for radical radiotherapy. The chapter also addressed the 
third component of the thesis, which was an evaluation of the impact of patient mobility on 
individual providers in terms of their net gains and losses of patients and how this relates to 
the level of competition faced by each hospital. The results have been presented in the form 
of the published paper. The supplementary material referred to in the paper is available at the 
end of this section.   
 
5.2 Research paper 3 
“Hospital quality factors influencing the mobility of patients for radical prostate cancer 
radiation therapy: a national population based study” 
 
The online PDF can be accessed at: 
http://www.redjournal.org/article/S0360-3016(17)33774-4/pdf  
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Supplementary Material 
 
Appendix 1. Flow chart of men included in the study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Men receiving radical radiotherapy from    
2010 – 2015 with Hospital Episodes Statistics 
(HES) linked Cancer Repository records 
46,654 
278 men excluded who lived 
outside of England: Isle of 
Wight (182), Wales (96) 
 
Men living in England who received radical 
radiotherapy at an English NHS provider  
44,860 
Matched to 57 providers of prostate cancer 
radiotherapy 
44,582 
 
Final cohort 
44,363 
 
219 men excluded as the 
treatment provider was not 
operational when the patient 
was diagnosed 
 
1794 men excluded who 
received palliative 
radiotherapy 
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6. RESULTS CHAPTER 4 
6.1 Impact of choice and competition on cancer service delivery 
The previous results paper evaluated the impact of patient mobility on individual radiotherapy 
providers in terms of their net gains and losses of patients. With respect to prostate cancer 
surgery, it was noted during the time-period of analysis (2010-2014) that some centres closed 
their radical prostatectomy service. At the same time, there was an increase in the numbers of 
centres performing robot-assisted techniques. Chapter 6 analysed whether there was an 
association between the net gains and losses of patients by individual providers and the 
intensity of hospital competition on both the observed closures of centres and the adoption of 
robotic surgical equipment. The results have been presented in the form of the published paper. 
The supplementary material referred to in the paper is available at the end of this section.   
 
6.2 Research paper 4 
“Effect of patient choice and hospital competition on service configuration and 
technology adoption within cancer surgery: a national population based study” 
 
The online PDF can be accessed at: 
http://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(17)30572-
7/fulltext?elsca1=tlpr  
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Supplementary Appendix 
 
 
Research in context – Evidence before this study  
 
 
Search criteria included: ((patient choice*[Ti/Abs]) OR consumer choice*[Ti/Abs]) OR 
patient preference*[MeSH Terms]) OR patient preference*[Ti/Abs]) OR patient 
mobility[Ti/Abs]) OR patient travel[Ti/Abs]) OR hospital referral*[MeSH Terms]) OR 
hospital referral[Ti/Abs])) OR hospital bypassing)) OR hospital choice[Ti/Abs])) OR 
hospital market[Ti/Abs])) OR hospital competition [Ti/Abs])) AND (((((((health care 
provider[MeSH Terms]) OR provider*[Ti/Abs]) OR hospital*[Ti/Abs]) OR 
doctor*[Ti/Abs]) OR Physician*[Ti/Abs]) OR "specialist care"[Ti/Abs])) AND cancer 
[Ti/Abs]))  
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7. RESULTS CHAPTER 5  
7.1 Impact of hospital competition on patient outcomes 
The fourth component of my thesis was an analysis of the impact of hospital competition on 
patient outcomes following prostate cancer surgery. The creation of a competitive 
environment to support patient choice and provide incentives for hospitals to compete with 
each other is in conflict with policies that seek to centralise services into fewer centres. 
Centralisation aims to improve quality by eradicating very low volume surgery, and to 
increase the number of procedures performed by remaining centres.  
 
This chapter compares the relative impact of both hospital volume and hospital competition 
on outcomes following a radical prostatectomy whilst adjusting for relevant case-mix criteria. 
The results have been presented in the form of the submitted research paper.  
 
7.2 Research paper 5 
“Impact of hospital competition and service centralisation on patient outcomes following 
prostate cancer surgery: a national population-based study” 
 
This paper has been embargoed pending open access publication. Hard copy of 
completed thesis available in LSHTM library.  
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8. RESULTS CHAPTER 6 
8.1 Hospital choice – a qualitative study  
The fifth component of the study utilised qualitative research methods to understand what 
factors inform and influence where patients choose to receive prostate cancer treatment. This 
involved interviews with men previously treated for non-metastatic prostate cancer in England 
between 2010-2015. The results have been presented in the form of the submitted research 
paper.  
 
8.2 Research paper 6 
“Hospital choice in the context of a cancer diagnosis: a qualitative study” 
 
8.3 Additional information  
Appendix A – Ethics approval (Page 204) 
Appendix B – Participant information sheet (Page 205) 
Appendix C – Consent form (Page 208) 
Appendix D – Interview topic guide (Page 209) 
 
This paper has been embargoed pending open access publication. Hard copy of complete 
thesis available in LSHTM library.  
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9. DISCUSSION 
 
This program of research has sought to address a number of questions that have persisted since 
the introduction of patient choice policies in the NHS. In the next section, I summarise the 
main findings from my PhD. Following this, I discuss how the findings of my thesis have 
furthered our understanding of the role and impact of choice and competition policies in the 
NHS before considering future opportunities for research.  
 
9.1 Summary of main findings 
The thesis demonstrates unequivocally that Choice and Competition are occurring within the 
English NHS. With respect to patient mobility for prostate cancer treatment, I find that one in 
three men and one in five men bypassed their nearest centres for prostate cancer surgery and 
radiotherapy respectively. Patient mobility varied significantly across English regions, with 
one in two patients bypassing their nearest surgical centre in London compared to one in seven 
patients in the North East Region. This pattern was related to the number of available providers 
from which patients could choose in their region, although mobility across regional boundaries 
was also evident, particularly for those men seeking prostate cancer surgery.  
 
Travel time was the dominant factor influencing location of care, however younger, more 
affluent men and those living in rural areas were more likely to travel further for radical 
prostate cancer radiotherapy. For prostate cancer surgery, the same pattern of patient 
characteristics was observed, however it was also found that fitter men with no comorbidities 
were also likely to travel further for treatment. Men are prepared to travel to centres where 
they think they will get the best care and outcomes. When considering the characteristics of 
each hospital within a conditional logit model, I find that for prostate cancer surgery, men 
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were attracted to centres that were early adopters of robot-assisted radical prostatectomy and 
to centres that employed surgeons with a national media reputation for prostate cancer surgery. 
For radiotherapy, men were attracted to centres that offered hypofractionated prostate 
radiotherapy as their standard schedule, to large-scale regional radiotherapy units, and to 
centres that were early adopters of intensity-modulated radiotherapy (IMRT) in the NHS.  
 
The mobility of patients has resulted in shifts in market share for individual cancer centres 
(both surgical and radiotherapy) resulting in a net gain of patients for some centres - “winners” 
- and a net loss of patients for others - “losers”. These patterns were more marked in areas of 
stronger competition as measured by a spatial competition index and resulted in some centres 
performing up to 400 more surgical or radiotherapy procedures than expected if they had only 
been treating local men for whom this was their nearest centre. Conversely, some centres were 
performing significantly fewer procedures (over 500 fewer in the case of one radiotherapy 
centre) than expected due to patients seeking care elsewhere. From an efficiency perspective, 
patient mobility is likely to have resulted in lengthening of waiting lists for some centres 
and/or wasted NHS capacity for others.  
 
The observed shifts in market share for individual surgical providers has also had an effect on 
service configuration and technology adoption as outlined in Chapter 6 (pages 87-98). 25% 
(n=10) of the 37 radical prostatectomy centres classified as “losers” closed during the study 
period with no evidence that their outcomes were any worse compared to those centres which 
remained open. Centres that gained patients were more likely to offer robotic surgery, 
compared to centres that lost patients (10/23 [43.5%], compared to 2/37 [5.4%]). Of the 10 
surgical centres that closed, none offered robotic surgery. It therefore appears that the co-
existence of policies that requires centres to perform a minimum number of procedures with 
policies that allow patients to select a provider of their choice has stimulated a form of natural 
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selection, where hospitals compete to preserve their cancer centre status. These competitive 
factors have likely contributed to the large-scale investment in robotic equipment in the NHS. 
Between 2010 and 2017, the number of robotic centres has more than tripled – increasing from 
1 in 5 (12/65) centres providing the technology in in 2010 to over three quarters (42/49) in 
2017. 
 
I also attempted to analyse the complex relationship between a competitive environment and 
patient outcomes following prostate cancer surgery. My findings demonstrate that patients 
treated in centres located in the most competitive areas (as measured with a spatial competition 
index) had a lower chance of a 30-day emergency readmission following surgery. However, 
there was no association between the strength of competition and other patient outcomes such 
as post-operative length stay and rates of severe urinary complications. The lack of a 
statistically significant association between hospital procedure volume and patient outcome 
after controlling for procedure type is likely to be influenced by the ongoing centralisation of 
NHS specialist services, which has served to eradicate surgical units that were performing a 
very low volume of procedures. Whilst one must be cautious in the interpretation of these 
results, my findings suggest that an association potentially exists between a competitive 
environment and clinical outcomes and that plans for further centralisation of surgical services 
may not necessarily deliver the expected improvements in outcome.   
 
Finally, the results of my qualitative work involving interviews with men previously treated 
for prostate cancer in the UK have been informative in understanding the factors that inform 
and influence patient choice. The findings demonstrate how the geographic configuration of 
specialist services, the perceived urgency of a cancer diagnosis and pre-established referral 
and treatment pathways all limit the opportunity to choose an alternative hospital. Patients 
were required to collect additional information independently and were mainly reliant on the 
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internet, the specialist nursing team and their individual social networks. This in itself creates 
socioeconomic inequities, enabling those with the relevant educational background, financial 
resources and confidence in negotiating care to potentially benefit from the best available 
treatment. However, in the absence of relevant up-to-date and interpretable information, 
patients were required to use a series of proxy measures and heuristics to differentiate quality 
and were particularly attracted to new technologies and “centres of excellence” (findings that 
are consistent with my quantitative results). A key advantage of the choice agenda is that it 
has enabled patients to “exit” care that does not meet their expectations or to bridge variations 
in the availability of specialist cancer treatments across the NHS.  
 
9.2 Policy implications 
The next section discusses how this program of research has enhanced our understanding of 
the way in which choice and competition policies are operating in the NHS, focusing on five 
key themes: Patient mobility, Determinants of patient mobility, Equity, Efficiency and 
Hospital competition.  
 
9.2.1 Patient mobility 
The first major finding from the thesis is that the proportion of patients prepared to travel 
beyond their nearest provider for cancer treatment has been far greater than was originally 
considered necessary (5-10%) to stimulate improvements in quality within a fixed-price health 
care market (Le Grand, 2009).   
 
Whilst studies to date have predominantly focused on patient mobility for surgical procedures, 
my findings within the context of radiotherapy are particularly informative. It suggests that 
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patients requiring complex daily treatments for up to 8 weeks are prepared to travel to 
alternative centres, despite the likely physical and financial burden associated with this.  
 
The extent of patient mobility observed is also unexpected given the current organisation of 
NHS specialist services and lack of clinician “buy-in” to these policies. In the current system 
patients are rarely, if ever, given a choice of treating hospital by their clinician, (Dixon et al, 
2010a) in part because clinicians are dis-incentivised from offering alternative hospitals for 
the same treatment given the loss of hospital income if the patient moved elsewhere for their 
treatment. This may result in patients not receiving treatment in line with their preferences 
(Bryan et al, 2006), or in patients failing to be informed about other relevant evidence-based 
treatments, which although not available at their local centre, could have been offered 
elsewhere.  
 
The overall rates of bypass are higher than expected given the substantial variation in the 
configuration of specialist services across English regions (i.e. concentration of available 
providers). For example, for prostate cancer surgery, the movement of patients between 
centres varied from one in two patients bypassing the nearest provider in London (in which 
there were 10 centres in 2010 covering an area of 1,572km2), to one in seven in the North East 
(in which there were 3 centres in 2010 covering an area of 8,592km2).  
 
This highlights that despite these geographic barriers, health care users are responsive to 
perceived differences in quality between centres and are prepared to exercise their right to 
“choose”. One could therefore argue that the rates of bypass observed could potentially be 
even higher if the current system was better aligned to support hospital choice. 
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It is unclear from the study findings, whether cancer patients are more sensitive to choice 
policies than non-cancer patients. The qualitative component of the study suggests that men 
diagnosed with prostate cancer attempted to balance the perceived urgency of their condition 
with a desire to do everything possible to secure the best outcome possible. It is not possible 
to extrapolate these results in the context of prostate cancer to other tumour types without 
further investigation, given differences in their mode of presentation, disease biology, 
treatment (type and intensity) and availability of services nationally. However, the systematic 
review I undertook (Chapter 3, pages 32-58), has been informative in identifying five 
international studies, which demonstrated that patients with different tumour types including 
breast, gastric, colorectal, and thoracic cancers are prepared to travel to alternative more 
distant centres for surgical treatment.  
 
9.2.2. Determinants of patient mobility 
By using a mixed methods approach, my thesis has provided an in-depth insight into the 
sources of information and the factors that influence patients’ choice of provider. It has 
highlighted that a fundamental issue within the current system, which undermines the choice 
agenda, is the failure by policymakers to provide relevant measures of quality across 
difference disease interventions. In the case of prostate cancer, there is little or no information 
at the provider level regarding the outcomes of different treatments in terms of tumour control 
and quality of life.  
Men instead were found to rely on a series of proxy measures to identify and differentiate 
quality between treatments and hospitals using information largely gleaned from the internet, 
their specialist cancer nursing teams and their individual social networks. Whilst one may 
point to the generic markers of quality that are currently presented on websites such as NHS 
choices (e.g. infection rates), evidence from my qualitative study and the wider literature 
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suggests that patients rarely use these metrics, as they are difficult to interpret and personalise  
in the context of their own disease (Dixon et al, 2010a; Fung et al, 2008; Hildon et al, 2012; 
Marshall & McLoughlin, 2010; Raven et al, 2012). In diseases such as prostate cancer, 
patients also have the added burden of having to assess the merits of competing treatment 
options as well as differences in the availability of treatment services nationally.  
 
The quantitative analyses found that men with prostate cancer were more likely to travel to 
centres that were early adopters of innovation such as robot-assisted radical prostatectomy or 
that had integrated new processes of care (e.g. hypofractionated radiotherapy). With respect 
to the former, this demonstrates the impact that the availability of innovative technologies has 
on perceptions of quality. This is likely to be partly influenced by current marketing literature 
available through websites and mainstream newspapers, which has a tendency to exaggerate 
the benefits of these innovations with respect to delivering improvements in outcome (Basto 
et al, 2015; Dixon et al, 2015).  
 
Similarly, the term “centre of excellence” was applied to specific providers by men 
interviewed in the study based on the perceived size of the centre, the volume of procedures 
performed, its research activity and the profile of individual clinicians. Whilst clinician and 
hospital reputation has previously been highlighted as a key determinant of patient mobility 
in survey based studies (Schwartz et al, 2005) the quantitative component of my thesis 
provides a better understanding about the impact of reputation on the behaviour of patients 
and the choices they ultimately make.  
 
One can therefore observe how choice and competition policies have the potential to favour 
particular providers irrespective of the outcomes they deliver, or indeed how providers 
including those delivering cancer services will adopt a competitive strategy to establish a 
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strong position in the market by differentiating their practices of care (Baker & Phibbs, 2002; 
De Kuijper, 2009; Lutz, 1991). New patients will gravitate to these places and by doing so 
create specialist centres that treat a large number of patients, which in itself will attract further 
patients.  
 
Another key determinant of mobility identified in the qualitative interviews was the desire for 
some patients to exit care that did not meet their needs or which they considered inadequate 
(Hirschman, 1970). It is arguable that this represents a success of the choice agenda and has 
allowed patients to access care that meets their own expectations, as previously this would not 
have been possible. However, a concern which arises is that some patients are moving to 
alternative cancer centres because the management plan at their local hospital is limited or 
does not take into account current advances in care. Whilst some individuals are clearly able 
to bridge these gaps, it remains unknown what the impact on outcomes are for those who are 
not able to evaluate differences in care or who do not have the financial resources to travel 
elsewhere.  
 
9.2.3 Equity 
Patient choice policies were expected to improve equity in access to the best available health 
care services for NHS patients, irrespective of their ability to pay (Le Grand, 2009). Prior to 
the introduction of these policies, patients could only choose an alternative hospital if they 
opted out of the NHS, and received care privately. However, the quantitative analyses 
demonstrate unequivocally a clear socioeconomic gradient in a patients’ willingness or ability 
to travel.  
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Younger, fitter and more affluent men were more likely to bypass their nearest provider for 
prostate cancer surgery, and younger and more affluent men for radiotherapy. The qualitative 
component of my thesis also supported these findings. It identified a subset of men who 
appeared to have inherent advantages based on socioeconomic status in accessing information, 
maximising their choice options, and benefiting from what they perceive to be the “best” 
health care.  
 
From a wider NHS perspective, there is a real concern that offering patients a choice of their 
treatment provider may widen socioeconomic inequalities in access to services and the quality 
of care received, especially where men from lower socioeconomic backgrounds are unable to 
move to higher performing centres due to economic constraints (Dixon & Le Grand, 2006; 
Fotaki, 2010). In addition, current patterns of mobility, may result in hospitals within 
socioeconomically deprived areas with older demographic profiles having to manage far more 
complex patient cohorts (both medically and socially), which will likely impact on their 
quality outcomes and ability to retain local patients.  
 
9.2.4 Efficiency  
My thesis demonstrates that patient choice policies have created “winners” and “losers” in the 
health system due to patients considering treatment in hospitals other than their nearest. I 
assessed this empirically by considering the difference between the number of patients treated 
in a centre and the number expected to be treated based on each patient’s residence. For some 
surgical centres, nearly 80% of patients for whom that centre was the nearest provider chose 
to have their treatment elsewhere. Conversely, other centres were performing up to 200% more 
operations than expected because patients from elsewhere travelled to these centres for their 
surgery. Similar findings were observed for radiotherapy providers in the NHS.  From an 
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efficiency perspective, patient mobility is likely to have resulted in lengthening of waiting lists 
for some centres and/or wasted NHS capacity for others.  
 
9.2.5 Hospital Competition  
In the NHS, policies promoting choice and competition are operating alongside those that aim 
to centralise specialist health care services.  The likely effect of these policies working in 
parallel on the equity, efficiency and quality of health care services was unknown at the time 
that choice and competition was introduced (Jones & Mays, 2009). Nor was there any 
guidance/evidence as to how these policies could be appropriately balanced. In this regard, 
the results from my thesis have been informative by highlighting from a conceptual point of 
view, two different ways in which competition is operating in the NHS and the implications 
on the wider health system of having a mixed-policy environment.  
 
The competitive environment 
The first way in which competition is influencing the delivery of health care is through the 
creation of a health care environment in which patients can select and travel to a health care 
provider of their choice. We know, from this program of research (and others), that patients 
are prepared to select and travel to a health care provider of their choice and that patient 
mobility is largely concentrated in the most competitive areas where there is a plurality of 
available providers (Damiani et al, 2005; Gaynor et al, 2013). This environment is thought to 
stimulate improvements in quality for individual hospitals as they seek to retain and attract 
new patients to prevent the loss of income and to also preserve their reputation (Le Grand, 
2009). This has been demonstrated in published studies which sought to analyse the impact of 
hospital competition on outcomes of medical and surgical care (Chou et al, 2014; Cooper et 
al, 2011; Diller et al, 2014; Hibbard et al, 2005).  
  
98 
 
In Chapter 6 (pages 87-98), we can see how a highly competitive environment influenced 
practices of care for prostate cancer surgery at the individual hospital level. I found that seven 
(41.2%) of 17 centres in the highest quartile for hospital competition were established robotic 
centres compared with five (10.4%) of the 48 other centres in the three other quartiles 
(p=0.0050). 
 
Given these observations from my own study and the wider literature, I attempted to analyse 
the relationship between a competitive environment and patient outcomes following prostate 
cancer surgery (Chapter 7, pages 99-128). I found that patients treated in centres located in 
the most competitive areas (as measured with a spatial competition index) had a lower chance 
of a 30-day emergency readmission following surgery. However, there was no association 
between the strength of competition and other patient outcomes such as post-operative length 
stay and rates of severe urinary complications.  
 
The results need to be considered cautiously given the limitations of the study, namely the 
paucity of patient outcome measures I had available, the lack of information about individual 
surgeon volume (which may be more relevant), and the underpowered nature of the study 
given it was an analysis of 65 centres.  In addition, the international literature to date has 
largely supported an association between increasing procedure volume and outcomes. 
However, the findings from my analysis suggest that an association potentially exists between 
a competitive environment and clinical outcomes for prostate cancer surgery, and that further 
centralisation may not deliver the expected improvements in outcome by increasing the 
volume of procedures performed.  
 
Further research using additional patient outcome measures and across different tumour types 
and interventions is required before any definitive recommendations can be made regarding 
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the relative merits of competition and centralisation as a mechanism to improve cancer 
outcome. This includes a better understanding of the impact of reconfiguring the health system 
to support either one of the two policies on the equity and efficiency of health care delivery, 
and the trade-offs that need to be considered if seeking to improve quality.   
 
Competition as a mechanism for centralisation - “survival of the fittest” 
A major finding from this research program is that patient choice and hospital competition, 
rather than a coordinated policy towards centralisation, have been the most significant drivers 
in the configuration of prostate cancer surgical services in the NHS. The incentive for NHS 
centres to compete has been two-fold. First, payment follows the patient, and therefore the 
loss of patients from their catchment areas affects hospital income and the viability of the 
service (Department of Health, 2012). Second, centralisation is largely driven by the need of 
a surgical service to meet procedure volume targets each year. Those centres not able to meet 
these targets are at risk of closure.  
 
This link between choice and competition and centralisation has not previously been observed 
in the NHS and highlights that whilst attempts have been made by policymakers to “control” 
the healthcare system centrally, it is in fact patients and clinicians that have had a substantial 
impact on the design of the health service. For example, centres classified as “losers” were 
more likely to close their service. In addition, the rapid and widespread adoption of robotic 
surgery in the NHS has been unforeseen, effectively rendering commissioning guidelines, 
published only in 2015 recommending a phased introduction of robotics for prostate cancer 
surgery within the NHS, obsolete. By 2015, 39 (71%) of the 55 centres open already offered 
robot-assisted radical prostatectomy.   
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Although the creation of a “survival of the fittest” environment was never explicitly intended 
within the original policy framework (Jones & Mays, 2009), some observers noted at the 
advent of such policies that it was an inevitability, and framed the potential consequences in 
both negative and positive lights.  
 
From a negative perspective, it was thought that the reconfiguration of services in response to 
patient demand rather than the health care needs of the population within a region, may lead 
to inequities in access to services for the most vulnerable groups given their decreased ability 
to travel (Paton, 2010). This has potentially been borne out in my study as patient mobility 
(and the subsequent shifts in market share for individual providers) was largely observed 
amongst younger, fitter, more affluent men. We also do not know whether the process of 
“natural selection” resulted in the closure of the worst performing centres (with respect to 
quality) or whether patients bypassing their nearest providers had better cancer outcomes.  
 
Observers also highlighted the potential inefficiencies that could result from such policies as 
providers seek to make themselves more attractive to patients, advising the government to 
heed lessons from the US health system, which had a well-established health care market at 
the time (Fotaki, 2014; Fotaki et al, 2008; Kuttner 2008; Pauly, 2005). The thesis demonstrates 
the case in point, as surgical centres investing in costly robotic equipment fared better than 
those who did not in attracting patients and reducing the threat of closure. However, there is 
little evidence that such investment and changes in practices of care have ultimately improved 
quality.  
 
From the perspective of the wider NHS, this should serve as a warning as to the potential 
inefficiencies that result from a lack of appropriate indicators regarding the quality of care to 
direct patient choice (Arrow, 2001).  In their absence, my thesis suggests that such policies 
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could lead to a technological “arms race” which may inflate the cost of delivering health care 
without any tangible improvement in outcomes.  
 
Whilst these have been the main concerns of the choice and competition agenda, many of 
which have been realised, others would argue that the current patient choice/hospital 
competition model is achieving exactly what has always been desired in the NHS. Simon 
Stevens (current Chief Executive of the NHS) wrote the following in support of competition 
in the BMJ in 2011(Stevens, 2011).   
 
“competition might diminish tiresome but repeated top-down NHS reorganisations and 
pointless bureaucratic restructuring, which history suggests are the inevitable result of day to 
day central government control. Imagine instead a world where clinicians controlled more of 
their own destiny, where those with creative ideas and innovative approaches were free to 
form new organisations or partnerships, and which would succeed based on the extent to 
which they met patients’ needs and preferences. This is a conception of the NHS not as a giant 
hierarchically organised healthcare factory—as now—but as an evolving, plural, distributed, 
and self directed health ecosystem. Many European healthcare systems operate more like 
that—why not the NHS?” 
 
My case study in prostate cancer surgery demonstrates that this vision of a dynamic evolution 
of services in response to patient preferences has become a reality. If working as intended this 
will serve to reduce inefficiencies in the current system by weeding out centres, which have 
the greatest net loss of patients. However, paradoxically, this is moving us away from the 
competitive environment on which these policies are predicated.     
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9.3 Balancing competition and centralisation 
The next section discusses how best to optimise the health care system if a mixed-policy 
approach is the preferred strategy within the NHS. i.e. a health care system, which seeks to 
maintain a competitive environment, continues top down reconfiguration of specialist 
services, and at the same time wishes to encourage dynamic changes in the delivery of services 
in response to patient demand.  
 
9.3.1 Designing a health system to support patient mobility and competition 
If the creation of a competitive environment is to be the dominant mechanism by which the 
health system delivers improvements in healthcare quality, the availability of alternative 
providers and the travel time between them are important factors (Balia et al, 2014; Damiani 
et al, 2005; Gaynor et al, 2010). The analysis of patients undergoing surgery and radiotherapy 
highlights how the spatial configuration of alternative providers (as measured with a spatial 
competition index) greatly influences the patterns of patient mobility and explains the regional 
variation we demonstrate. As a result, the geographical layout of cancer services means that 
not all centres face the same competitive pressures and in turn they will respond differently to 
choice and competition policies as a mechanism for quality improvement.  
To increase the level of competition across England, new specialist cancer providers would 
be required, especially in regions such as the North East of England, Yorkshire and 
Humberside, and the East of England. In designing the optimum geographic location of new 
specialist centres, location allocation modelling, provides a robust empirical approach by 
accounting for existing patterns of mobility, clinical quality and hospital capacity within the 
health service (Santibáñez et al; Wang & Onega, 2015). 
 
  
103 
 
9.3.2 Top down reconfiguration of cancer services  
In the current policy environment it is unclear how strategic plans for the reconfiguration of 
specialist cancer services are being formulated (e.g. NHS cancer alliances or cancer 
vanguards) (Independent Cancer Taskforce, 2015). It is imperative that such decisions are 
based on substantive evidence that centres provide either the best care, improved access or 
have the capacity to expand their services in the context of increasing demand, rather than be 
based on the perceived profile or reputation of a centre.  
 
Two empirical approaches to the reconfiguration of services using econometric and 
geographic methods could be considered to assist in this complex process. Econometric 
analyses can be used to predict the impact of the closure of cancer treatment units on travel 
times, equality in access and outcomes using data on an individual’s willingness to travel and 
quality preferences derived from the conditional logit analyses undertaken in this study 
(Kobayashi et al, 2015; Poeran et al, 2014). Pilot closures may be based on several relevant 
factors, for example closing the: (1) worst performers (if outcome data is available), (2) low 
volume centres, (3) centres that are frequently bypassed and therefore potentially represent 
wasted NHS capacity, (4) or those centres which do not have all cancer treatment modalities 
available onsite (e.g. radiotherapy and surgery). In this way, one can simulate multiple options 
for service reconfiguration, and assess their likely health system effect.  
 
Similarly, using willingness to travel coefficients, geographical techniques such as location 
allocation modelling as described before, can identify which treatment centres to close in order 
minimise disparities in access to cancer care (Wang & Onega, 2015). This involves a step-
wise approach that considers the impact of closures of each centre in the choice set before 
assigning which closure is likely to have the least impact on access expressed in terms of travel 
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time or distance. This is important as inequities in access have been observed for older, and 
lower socioeconomic groups with comorbidity, which can subsequently affect outcomes.  
 
9.3.3 Development of indicators for quality improvement  
If a bottom-up approach (led by patients and clinicians) to service configuration and quality 
improvement is the preferred strategy within the NHS, efforts need to be made to fill the 
current gaps with respect to information about the quality of cancer treatment (both surgery 
and radiotherapy) delivered by individual providers. This information needs to be provided in 
a format that is interpretable for patients and will assist in their decision making (Department 
of Health, 2016). The qualitative component of my research demonstrated the current 
information anarchy that exists in prostate cancer with little if any independent information 
about aspects of care that patient’s value, for example, their likely functional and oncological 
outcomes from treatment.  
 
Instead, patients remain reliant on a variety of different types and sources of information (e.g. 
word of mouth, the internet, personal knowledge) as well as the media interpretation of 
technological developments (Abrishami et al, 2014; Dixon et al, 2010a; Victoor et al, 2012). 
In addition, specialist centres continue to differentiate their practices of care which adds 
further complexity for patients when considering what are the best treatments and who are the 
best practitioners.   
 
It is a recommendation of this thesis that the development and reporting of patient-level 
outcomes for interventions  should be undertaken as part of a public engagement strategy, 
which seeks to better understand what the public wish to see reported with regards to the 
quality of care delivered by individual cancer providers and clinicians. Whilst most attention 
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has been devoted to the development of outcome measures which reflect the quality of 
treatment, in reality there are many other aspects of quality that patients are likely to value and 
would wish to see reported. A public engagement approach can also assist in the development 
of an online platform, which allows individuals with cancer and their carers/relatives to better 
assess differences in the quality of care and provide guidance on the value of new innovations 
that are increasingly marketed and publicised in the media (Aggarwal et al, 2014).  
 
With respect to outcome indicators, it is important to acknowledge that it may be difficult (or 
not ever be possible) to develop meaningful indicators for some tumour types. For example, 
the appropriateness of many indicators that are currently available is problematic because they 
can only be published or measured after a long lag period (e.g. side-effects/survival rates at 1 
and 5 years) during which time clinical practice can change considerably (Walker et al, 2013). 
Neither is it helpful to merely publish a series of process indicators, which may be difficult 
for patients to interpret and do not necessarily help to differentiate the quality of care between 
providers (Danielson et al, 2011). It is also not clear as to the level at which these outcomes 
should be reported, for example at the individual hospital or clinician level. There is an 
ongoing debate within the surgical arena as to whether individual surgeon volume is a stronger 
predictor of outcome than hospital level procedure volume. However, moves towards clinician 
based outcome reporting are controversial (Jenkins & Cooper; Trinh et al, 2013), and may 
prove particularly challenging for radiotherapy given the multidisciplinary nature of treatment 
delivery.   
 
Despite these limitations, the current Secretary of State for Health - Jeremy Hunt - remains 
firmly committed to the transparent reporting of outcomes on sites such as MyNHS (Jeremy 
Hunt, 2017). In addition, progress continues to be made in the development of clinically 
relevant quality measures. For example, indicators reflecting aspects of the quality of prostate 
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cancer surgery and radiotherapy have been recently developed using administrative datasets 
by the National Prostate Cancer Audit (Royal College of Surgeons of England, 2016c; 
Sujenthiran et al, 2017a). They have helped to define differences in the outcomes between 
alternative treatment techniques (e.g. Intensity modulated radiotherapy versus 3D conformal 
radiotherapy) (Sujenthiran et al, 2017a; Sujenthiran et al, 2017b) and are now being used to 
differentiate the quality of treatment at the level of individual providers. These indicators await 
formal inclusion in the Clinical Outcomes Program which is an initiative that since 2013 aims 
to publish quality measures at the level of the individual consultant, team or unit (Health 
Quality Improvement Partnership, 2016). 
 
9.4  Strengths and Limitations  
The strengths and limitations of specific methods and analytical approaches have been 
discussed in the preceding chapters, and this section will focus on more overarching themes. 
 
9.4.1 Methodological approach 
A key strength of the thesis has been the use of quantitative and qualitative research methods, 
which has meant that the findings are nuanced and more attentive to the effect of such on 
policies on individuals as well as the overall patient group. Throughout the thesis, I have 
attempted to keep the patient as the main focus, understanding how individual characteristics 
(e.g. socioeconomic status) impact on their ability to travel to alternative hospitals and in turn 
to understand the factors which potentially influence where they ultimately decide to receive 
treatment. Much of the discussion around the impact of “choice” would have been lost if a 
singular approach had been undertaken.  
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In addition, the design of the study has enabled each method to inform the other. In particular, 
the systematic review of the literature informed the quantitative approach to investigating 
patient choice and in conjunction with the qualitative interviews identified factors influencing 
patient mobility, which could subsequently be assessed within the quantitative model. Both 
quantitative and qualitative analyses were undertaken during the same time-period and 
ensured that the methods and specific areas of investigation continually evolved as part of an 
iterative process. 
 
9.4.1 Data 
A major strength of my thesis was that it used linked national level patient datasets. Only a 
small proportion of total number of NHS patients (1-2%) receiving either surgery or 
radiotherapy during the time-period of analysis were excluded. Exclusions predominantly 
related to men either residing outside of England or because they received treatment at an 
unrecognised surgical or radiotherapy provider.  
 
The NHS itself is an ideal forum for understanding the impact of patient choice policies. It is 
a national single-payer, tax-based system, in which care is free at the point of access and not 
based on ability to pay for insurance or treatment. Since 2008, patients have access to all 
available NHS providers in England with no explicit restrictions on the choices available. I 
was careful to ensure the choice-set of available centres was accurate and included closures 
or openings of centres during the time-period of analysis.  
 
Previous analyses focusing on patterns of patient mobility have used regional, or insurer-based 
patient databases or limited national samples of patients (Ho, 2006; Messina et al, 2013; Pope, 
2009). There has been a lack of clarity regarding whether the “choice set” of hospitals from 
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which patients are expected to choose actually perform the procedure in question (Chernew et 
al, 1998). In addition, many studies perform an aggregated analysis that attempts to look at 
mobility patterns for multiple elective interventions or mixed acute/elective patients 
(Kronebusch, 2009). This fails to understand the nuances affecting particular treatment 
decisions for specific diseases and interventions. Many also do not account for pre-existing 
specialist referral patterns based on insurance status (e.g. preferred providers) or the influence 
of co-payments on patient choice (Escarce & Kapur, 2009; Ho, 2006).  My analysis of the 
radiotherapy dataset (RTDS) was particularly unique, as there are few databases 
internationally that provide such detail with respect to total doses and fractionation schedules 
and allowed me to analyse the impact of variations in radiotherapy practice on patient 
mobility.  
 
The main issue with respect to the data was the high proportion of patients with missing cancer 
staging information (approximately 25-30%). I was therefore not able to assess the impact of 
cancer stage on the patterns of patient mobility observed. However, given that disease stage 
is unlikely to preclude treatment at any one location (surgical and radiotherapy centres are 
able to readily treat patients with intermediate and locally advanced disease (Royal College of 
Surgeons of England, 2016c)) the impact on patient mobility is likely to be small.   
 
Comorbidity scores (presented as the RCS Charlson Score (Armitage et al, 2010)) were 
available using the HES dataset and the inclusion of this information for each individual 
patient as a co-variate, offered insight into the impact of a patients’ fitness on their propensity 
to travel beyond their nearest hospital.  
 
Ideally, the analysis would have used patient postcodes to identify their residence, however 
these were not available due to data restrictions. Lower layer super output areas (LSOAs) were 
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used instead. These encompass approximately 650 households (1500 residents) and the 
geographic point coordinates used in the analysis were centred on the most population dense 
areas within the LSOAs to improve accuracy (population-weighted centroids). Other studies 
have used Middle Layer Super output areas, which cover a population of 5000 residents, or 
GP post-codes which are not as precise. The use of LSOAs will have added “noise” in the 
evaluation of travel times which will have attenuated rather than enhanced the observed 
relationships.  
 
9.4.2  Patient choice 
As discussed in the introduction, it is not possible to ascertain empirically from administrative 
data whether patients have made an active choice to receive care at a particular centre. The 
thesis therefore used patient mobility as a proxy measure as it can be quantified. This is a 
strength of the study as it appreciates the complexity of investigating choice and what can be 
inferred using quantitative data. In the wider literature, quantitative studies using similar 
methods that claim to have quantified patient choice (predominantly in the health economics 
literature) are in fact only describing patterns of mobility. It is for this reason I used a mixed 
methods approach to understand the complexity of patient choices in the context of a cancer 
diagnosis 
 
The thesis was unable to assess the impact of the patient’s GP on a decision to move. Given 
that the GP has no incentive to refer to any one provider in the NHS, it is accepted that many 
such decisions are made in partnership and to separate the relative impacts on decision-making 
is empirically very challenging.  
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9.4.3 Travel time estimation.  
My model uses average drive times, which is the standardised methodology for these analyses 
and considered superior to straight-line distance. However, I do acknowledge that drive times 
are variable depending on the time of day, which may affect patient’s decision-making. In 
addition, public transport times were not available for this analysis. The use of public transport 
times would be recommended for future work and could act as a sensitivity analysis.  
 
Our estimation of hospital bypassing may be affected in circumstances where men reside at 
the boundaries of two different specialist multidisciplinary (SMDT) networks for prostate 
cancer (Aggarwal et al, 2016). For example, whilst the diagnostic centre they initially present 
to may be their closest hospital, the surgical or radiotherapy centre associated with this 
diagnostic centre as part of the SMDT network may be located further away from the patient’s 
residence than the surgical centre of a different SMDT network. This may affect the 
estimations of the proportion of bypassers in both directions. For example, patients initially 
offered treatment at a more distant radiotherapy centre, may request to receive care at their 
nearest radiotherapy centre instead, which would mean they are technically “non-bypassers” 
according to the definitions used, despite choosing to change their treatment location.  
 
9.4.5 Determinants of mobility  
A major limitation of the study is that performance measures that accurately reflect the quality 
of prostate cancer treatment are currently not available. As a result, the study uses a series of 
proxy measures to define quality as well as other hospital factors, which could influence a 
decision to move. The hospital characteristics considered were informed by the peer-reviewed 
literature, in depth qualitative interviews, and the National Prostate Cancer Audit 
Organisational survey (Royal College of Surgeons of England, 2014).  
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A notable exclusion was waiting times for procedures as some patients may have considered 
moving to alternative providers to receive quicker treatment. However, extensive efforts have 
been made in the English National Health Service to ensure prompt diagnosis and treatment 
of suspected cancer patients through a system of defined targets. In 2014/2015 95.3% of 
people treated for urological cancers in the NHS began their first definitive treatment within 
the 31 day target (NHS England, 2015).  
 
Other potential determinants of mobility such as care giver/work location were not available 
in our dataset. Procedure volume was considered as a covariate, however this information was 
not publicly available during the time of the analysis to inform patient decision-making and 
therefore not included.  
 
9.4.6 Competition  
The study used a spatial competition index as a proxy measure for competition. A number of 
measures are proposed in the literature, of which the most commonly used metric is the 
Herfindahl-Hirschman Index (HHI), which is a measure of market concentration (Wong et al, 
2005). It is calculated by squaring the market shares of individual providers (number of patient 
predicted to be treated or actually treated by each centre) in a particular market area. If there 
is an equal split of patients between centres then it is considered a market with low 
concentration. Equally, if there is one dominant centre in the market area, this is considered a 
concentrated market. My empirical analysis did not use HHI as there was no established 
definition for market structure with several alternatives used in the literature depending on the 
availability of data (Cooper et al, 2011; Gaynor et al, 2013; Gravelle et al, 2012). In addition, 
a hospital which has lots of nearby competitors but attracts the majority of patients due to 
perceived quality in their market area would be considered to be in a monopoly environment.  
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Instead, I decided to use a spatial competition index, as a measure of the external competition 
faced by each individual treating centre. This metric accounts for the demand for services 
(number of eligible patients) and the availability of alternative hospitals within 60 minutes 
drive time. This was adapted from other studies (Gravelle et al, 2012) which have previously 
used this measure of competition, and was preferred for this analysis, as it took into account 
regional variation in the availability of alternative providers and provided an ideal measure of 
a hospital’s competitive environment.   
 
9.4.7 Patient outcomes 
A major limitation of the thesis is the lack of more recent data on patient outcomes of surgical 
treatment quality including rates of incontinence, sexual dysfunction and tumour margin 
status. In addition, it was not possible to factor in individual surgeon volume. However, one 
could argue that this sums up the current policy context in which decisions regarding the costly 
reconfiguration of services are being undertaken without national level evidence that they will 
ultimately improve outcomes.  
 
The recent PROMS exercise undertaken by the National Prostate Cancer Audit would mean 
that further evaluation using more sensitive measures of treatment quality could be undertaken 
in the future. Equally, since the study period of analysis in the paper (2008-2011) the number 
of prostate cancer surgical centres has decreased from 65 to 49. The analysis could therefore 
be repeated in the future to assess the relative impacts of “centralisation” and “competition” 
on quality as part of a difference in differences approach.  
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10. CONCLUSION 
 
Choice and competition policies were introduced in the NHS on the supposition that they 
would drive up quality, enhance equity in access, and afford patients greater choice and control 
of their health care. The thesis demonstrates that patients with cancer are prepared to travel in 
significant numbers, to alternative more distant centres for treatment, based on where they 
think they will get the best care and outcomes. Health care providers in turn appear to be 
adopting a competitive strategy aiming to attract new patients using specific branding or 
special ingredients (e.g. new practices or processes of care) whilst not necessarily improving 
the quality of care delivered. The patterns of mobility observed are inequitable and are largely 
manifest by younger more affluent patients. There is also evidence that such policies create 
inefficiencies in the delivery of specialist prostate cancer services by increasing costs and 
having a negative impact on capacity.  Finally, the overall impact of hospital competition on 
improving patient outcomes remains unclear and policy makers need to proceed with caution 
when considering the optimum reconfiguration of health services in the absence of hospital 
level data on outcomes.   
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11. TRAINING 
 
As part of my Doctoral Research Fellowship funded by the NIHR I have undertaken training 
in research methods relevant to my PhD study as outlined below. 
 
Quantitative  
 
 Introduction to STATA – Imperial College London  
 Analysing patient level data using Hospital Episode Statistics – University of York  
 Introduction to Arc GIS – University of Southampton  
 Advanced Arc GIS – University of Southampton  
 Statistical Methods in Epidemiology – LSHTM 
 Choice modelling and stated choice survey design – University of Leeds 
 
Qualitative 
 
 Qualitative Research Methods – Oxford University  
 Qualitative Methodologies – LSHTM 
 Nvivo – University of Surrey 
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13. APPENDICES 
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Appendix B – Participant information sheet  
Experience and management of prostate cancer  
We would like to invite you to take part in our research study. Before you decide whether 
you would like to, please read this information so you know what the study is about and 
what taking part means for you.   
 
What is the study about? 
We would like to better understand how men with prostate cancer are being treated. We 
are especially interested in how patients’ choose their treatment and where they are 
treated. We intend to do this by talking to men who have been diagnosed with non-
metastatic prostate cancer in the last three years. We want to understand the patient 
journey and the process men go through when making decisions regarding their care. This 
will help guide what information is needed to help people with their choices and how best 
to organise cancer services in England to improve the quality of care.   
 
Who is carrying out this study? 
The study is led by a researcher from the London School of Hygiene and Tropical Medicine 
(LSHTM) (see www.lshtm.ac.uk) who works within cancer services in the NHS. He will be 
supported by a team of researchers who specialise in cancer services and health care 
quality improvement. The study is funded by the National Institute for Health Research 
(NIHR) (see www.nihr.ac.uk).  
 
Why have I been asked? 
The regional leads of “Tackle Prostate Cancer” have agreed for the research team to 
approach its members within the local prostate cancer support groups in England. You have 
been asked as we want to understand the experiences of men with prostate cancer. We are 
interested in the choices people make about going to healthcare services and the support 
they receive when making important decisions regarding their care.  
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What does taking part involve? 
We would like you take part in a one-to-one interview with the lead researcher. This would 
be at a time convenient for you. We anticipate that the interview will last between half an 
hour and an hour and it will take place by telephone or Skype. The interview will involve 
discussing your views, opinions and experiences in greater detail. If you would prefer the 
interview to be done face to face, arrangements can be made to make this possible.  
 
Do I have to take part? 
Your contribution is very important to us but it is entirely up to you. If you do take part, you 
don’t have to answer all the questions and you can end the interview at any time.  
 
What will happen to the information I give? 
This study will help health professionals to improve the care we can provide to men with 
prostate cancer and potentially other cancers. Everything you tell us will be strictly 
confidential.  No one will be able to trace anything said in the interview back to you as an 
individual. Data and results from this study will not include any names or identifying 
information and will be stored securely in line with the research team’s policies.  
 
What’s in it for me? 
We have found that people find being interviewed a positive experience. It’s an 
opportunity to talk about your life to an attentive listener. At the same time you will be 
contributing to research of national importance which may have an impact on the care that 
other men in a similar situation receive.  
 
What do I do if I am interested in taking part? 
If you are interested in taking part we would be grateful if you could reply to the 
introductory email/letter sent by the “Tackle Prostate Cancer” regional lead indicating you 
would be happy to be contacted about the study. Following this one of the research team 
will phone you to talk to you about whether you would like to take part in an interview and 
answer any questions you may have about the study.  
 
If you have any questions or would like to know more, please contact:  
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Dr Ajay Aggarwal 
London School of Hygiene & Tropical Medicine 
15-17 Tavistock Place 
London WC1H 9SH 
phone: 07714750203 
e-mail: ajay.aggarwal@lshtm.ac.uk 
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Appendix C – Consent form 
Experience and management of prostate cancer 
Consent form 
Please read the following statements, initial those you agree with in the box on the right, 
and then sign your name at the end: 
 
Name of participant                            Signature                              Date 
   
 
If you would like more information, please contact: Dr Ajay Aggarwal email: 
ajay.aggarwal@lshtm.ac.uk 
1. I confirm that I have read the information sheet for the above study and have 
had the opportunity to ask questions. 
 
 
2. I agree to take part in an interview.  
 
 
3. I agree to the interview being audio recorded. 
 
 
4. I understand that all information I give during the interview will be strictly 
confidential. 
 
 
5. I understand that the results of the study will be anonymised. This means that 
no one will be able to trace anything I say during the interview back to me. 
 
 
6.  I understand that anonymised, unidentifiable quotes of mine may be used in 
reports of the study. 
 
 
7. I understand that my participation is voluntary and that I can stop the interview 
at any time without giving any reason. 
 
 
8. I am willing for members of the project research team to have access to my 
anonymised responses. 
 
 
9. I understand that anonymised information I give may be reviewed by the 
authorities responsible for regulating the study (the London School of Hygiene 
& Tropical Medicine).  
 
 
10. I am willing for the anonymised information that I give to be stored in a secure 
data repository if required. 
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Appendix D –Interview topic guide 
Initial narrative 
 When did you first get a sense that things weren’t right?  
o What were you thinking at that time? 
o Did you search for any information or speak to anyone at this stage? 
 
 Who did you go to for advice?  
 
Initial GP consultation  
 What was recommended?  
o If referral for diagnosis recommended – were you given a choice of where 
you could be referred?  
o If no – would you have liked to be offered a choice? Was it important to you 
at this time? (see next section – place of diagnosis) 
o Did you request an alternative referral? If yes why?  
 
 How did you decide where to go? (If yes to latter question or first question) 
o What options were you considering? 
o What information sources did you use?   
o Did you speak to anyone?  
o What factors were most important in your decision? 
 
Place of diagnosis 
 What hospital were you referred to?  
o How did you feel about being referred there?  
o Had you or anyone you knew had any experience of the hospital that you 
were being referred to?  
o Did you know anything about the consultant or department?  
 
What happened after the referral? – (e.g. tests etc) 
 Did you search for any information or speak to anyone regarding your referral? 
(Note this is a trigger for information seeking and interpretation) 
 What investigations did you have and where? 
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 Diagnosis  
 At what stage were you given the diagnosis? (if not discussed in relation to 
previous question) 
o Who did you see? Was this at the same hospital you were initially referred?  
o Did you have any expectations or preferences before the consultation? 
 
 How did you feel when you were given the diagnosis? 
o What was explained to you about the processes you were going to go 
through? 
 
 If diagnosis and treatment discussion not at the same stage refer to information 
seeking section first?  
 
 Overall - how did you feel about the consultation (and the physician) and the 
information you were given? (Reassured/trust/sufficient info? ) 
 
Treatment options 
 At what point did the discussion regarding treatment take place and with 
whom?  
o Did you feel in a position to have a discussion about treatment at that stage? 
o Did you have any other treatment options in mind at the time of the 
meeting?  
 
 What options were you given with regards to treatment and where you might 
have it? 
o Was the planned location of treatment where you expected it?   
o Had you heard anything/had experience of these hospitals before?  
 
 Did you ask about any other treatments/hospitals? 
o Did you request a referral elsewhere?  
o If yes - Did you feel comfortable doing this? How did the clinician respond? 
o If no would you liked to have been given a choice of other options?  
 
 What factors were most important to you when considering the options?  
o (If not discussed in above question) Was the location of the treatment 
important to you? – Would you have considered any other locations for your 
treatment? 
 
 What information were you given? – leaflets/experiential 
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 Did you have an opportunity to talk to anyone else at this stage? 
 
 How were things left at the end of the consultation? 
o Did a decision have to be made at this time?  
o Time frame for decision making? Await further appointments? 
 
 Did you feel in a position to make a choice at this stage? ( if requirement to 
choose at this stage) 
 
 Overall - how did you feel about the consultation (and the physician) and the 
information you were given? (Reassured/trust/sufficient info? ) 
 
Information seeking and interpretation 
 What happened when you got home? 
o Had you had any experience of cancer – personally or someone else?   
o Who did you speak to? (GP, friends, family, specialist nurse) 
 
 Did you search for any information yourself?  
o If no did anyone search for any information on your behalf? 
o If yes - What motivated this decision?  What were you looking for and why? 
 
 Were you considering any other treatments or locations?  
 
 What type of information did you find?  
o Was the information you found helpful?  
o Were you able to understand the information? Did you Trust it?  
o How did you process the information/what weight did you attach to the info 
sources? 
o Did you look at any NHS choices or Doctor Foster websites?  
 
 What information would you like to have been given?  
 
 How did the conversations you had or the information you found affect your 
decision making or choices?  
 
Follow up consultation 
 What happened at the follow up consultation? Who did you see? 
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o Did you enquire about any other options or ask for a referral elsewhere? 
o How did the clinician respond? How did you feel about doing this? 
 
 Were you able to go to the hospital or receive the treatment that you wanted? 
 Overall - how did you feel about the consultation (and the physician) and the 
information you were given? (Reassured/trust/sufficient info? ) 
 
Location of Treatment 
 Where did you have your treatment in the end?  
 How did you get there? 
 Was there anything particularly good or bad about the hospital? 
(probe – something particular bad about the hospital you were receiving treatment in or 
something that would have attracted you to a different hospital?) 
 
Decision making/choice 
 Looking back on it now, do you feel like you made the decision or would you 
describe it differently? 
 Do you feel comfortable with how decisions were made about your treatment? 
(probe – explore at the time? And now?) 
 Do you feel you had much choice in the decision making process? 
(probe – would you have preferred things to be different, in what way?) 
 
Closing Questions 
 Is there anything else you would like to tell me about? 
 
 
 
 
 
 
